AI Analysis
AI-generated analysis. Always verify with the original filing.
Revenue was $5.0K Operating Income was -$4.2M Net Income was -$4.2M Eps was $-2.20
Key Takeaways
1FY2025 GAAP revenue totaled $5.0k, with no revenue generated from product sales to date.
2FY2025 GAAP operating loss was $4.2M and net loss was $4.2M, aligned with expected preclinical pipeline development expenditures.
3GAAP diluted earnings per share for FY2025 was -$2.20, reflecting the period's net loss.
4FY2025 net cash used in operating activities was $2.9M, with $98k in capital expenditures allocated to equipment for the obesity and metabolic disorders program.
5Management has confirmed current capital resources are insufficient to fund planned operations for at least one year following this 10-K filing date.
6The company expects to continue incurring significant operating expenditures and net losses for the foreseeable future as it advances its preclinical oral obesity candidate.